ENDPOINTS

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Plus, news about Sumitomo Pharma, Gilead, Roche, Desentum, Inhibrx and Pila Pharma: Roche's Ocrevus fails high-dose study: The Phase 3 study looking at a dose higher than the approved dose of 600 mg of Ocrevus ...

Apr 2, 2025 - 18:43
 0
Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix
Plus, news about Sumitomo Pharma, Gilead, Roche, Desentum, Inhibrx and Pila Pharma: Roche's Ocrevus fails high-dose study: The Phase 3 study looking at a dose higher than the approved dose of 600 mg of Ocrevus ...
Read More

Tags:

Previous Article

NASA Research Examines the Multicellular Behavior of Unique Bacteria

Next Article

Tiny, Injectable Pacemaker Runs on Light and then Dissolves

Related Posts

Updates from Washington; A trio of Big Pharma deals; What do recent share buybacks mean for M&A?; and more

Updates from Washington; A trio of Big Pharma deals; Wh...

Feb 15, 2025  0

AstraZeneca buys FibroGen’s China unit for local control of anemia drug

AstraZeneca buys FibroGen’s China unit for local contro...

Feb 20, 2025  0

FDA critiques 'misleading' Taiho promotion of bile duct cancer drug

FDA critiques 'misleading' Taiho promotion of bile duct...

Mar 26, 2025  0